Introduction {#sec1}
============

Ovarian estrogens play a major role in the regulation of energy homeostasis ([@bib10; @bib18; @bib25]). Decreased levels of estradiol (E2) after menopause or ovariectomy (OVX) are also associated with hyperphagia, reduced energy expenditure, and weight gain ([@bib39; @bib25]). In turn, E2 replacement therapy prevents OVX-induced obesity by decreasing feeding and increasing energy expenditure ([@bib10; @bib8; @bib25]). Likewise, hormone replacement therapy reverses the development of obesity and metabolic dysfunctions in postmenopausal women ([@bib53; @bib25]). Studies have also suggested variations in meal size and body weight in rats depending on the stage of the estrous cycle ([@bib46]), as well as during pregnancy and lactation ([@bib12]).

Genetic models of loss of function of estrogen receptors (ERs), which are widely expressed in the hypothalamus ([@bib44]), have demonstrated that mice with global or brain-specific targeted disruption of ER alpha (ERα) are obese, as a consequence of hyperphagia and hypometabolism ([@bib17; @bib54]). Similarly, mice and patients deficient for the aromatase enzyme, which mediates the conversion of androgens to estrogens, develop obesity ([@bib13; @bib19; @bib20]). Interestingly, estrogens display a nucleus-specific action within the hypothalamus to modulate energy balance, particularly within the arcuate (ARC) and ventromedial (VMH) nuclei. VMH-specific delivery of adeno-associated viral vectors silencing ERα in mice and rats leads to marked obesity, impaired glucose tolerance, and reduced energy expenditure ([@bib32]). Of note, these genetic manipulations did not alter food intake, indicating that estrogens actions in the VMH modulate specifically energy expenditure. In keeping with this, female mice lacking ERα in hypothalamic steroidogenic factor-1 (SF1) neurons of the VMH exhibit reduced energy expenditure and brown adipose tissue (BAT)-mediated thermogenesis, leading to obesity, despite normal feeding ([@bib54]). In contrast, deletion of ERα in proopiomelanocortin (POMC) neurons of the ARC leads to hyperphagia without changes in energy expenditure ([@bib54]). Finally, concomitant deletion of ERα from both SF1 and POMC neurons recapitulates both phenotypes, causing hypometabolism, hyperphagia, and severe obesity ([@bib54]).

Despite this evidence, the molecular and cellular events mediating E2-induced negative energy balance and BAT thermogenesis remain elusive. Thus, the aim of this study was to investigate the hypothalamic mechanism mediating E2-induced thermogenesis. We show that central E2 regulates BAT thermogenesis through ERα and activation of the sympathetic nervous system (SNS) by modulating hypothalamic AMP-activated protein kinase (AMPK), specifically in the VMH.

Results {#sec2}
=======

Peripheral E2 Induces Negative Energy Balance {#sec2.1}
---------------------------------------------

OVX rats gained significantly more weight and developed a marked hyperphagia ([Figures 1](#fig1){ref-type="fig"}A and 1B). Subcutaneous (SC) treatment of OVX rats with E2 induced a marked reduction in body weight and food intake ([Figures 1](#fig1){ref-type="fig"}A and 1B) leading to a state of negative energy balance ([Figure S1](#app2){ref-type="sec"}A available online). OVX rats showed the expected increase in serum luteinizing hormone (LH) and decrease in circulating E2 levels (confirming the efficiency of the OVX procedure), while SC E2 treatment recover both parameters to physiological levels ([Figures S1](#app2){ref-type="sec"}B and S1C). For this reason, and in order to avoid a possible interference of fluctuations of ovarian E2 production during the estrous cycle, we used OVX rats in all the experiments (with the exception of [Figures 7](#fig7){ref-type="fig"} and [S7](#app2){ref-type="sec"}A--S7C, where intact rats were used).

The anorectic effect of E2 was found to be associated with decreased NPY mRNA and increased POMC mRNA levels in the ARC of OVX rats treated with E2 ([Figures 1](#fig1){ref-type="fig"}C and 1D). E2-treated rats showed decreased phosphorylated levels of AMPKα (pAMPKα) and ACCα (pACCα, which is inactive when phosphorylated) in the whole hypothalamus ([Figure 1](#fig1){ref-type="fig"}E). Consistent with ACC activation, we found that E2 increased the hypothalamic malonyl-CoA levels ([Figure 1](#fig1){ref-type="fig"}F). To establish the functional dependence of E2's actions on hypothalamic AMPK and malonyl-CoA levels, we investigated whether pharmacological activation of central AMPK could reverse the anorectic effects of E2. Intracerebroventricular (ICV) administration of the AMPK activator AICAR decreased hypothalamic malonyl-CoA concentration ([Figure 1](#fig1){ref-type="fig"}G) and reversed the hypophagia observed in rats treated with E2 ([Figure 1](#fig1){ref-type="fig"}H).

E2 Modulates the Thermogenic Program in BAT Independently of Food Intake {#sec2.2}
------------------------------------------------------------------------

To dissect the relative contribution of the anorectic effect of E2 to its impact on energy homeostasis, a group of vehicle-treated pair-fed rats (i.e., received the average amount of food eaten by the E2-treated rats the day before) was studied. SC administration of E2 to OVX rats decreased body weight largely exceeding that of pair-fed OVX rats, indicating a food-independent weight loss ([Figures 2](#fig2){ref-type="fig"}A and [2](#fig2){ref-type="fig"}B). SC administration of E2 increased the mRNA expression or protein content of thermogenic markers, such as uncoupling protein-1 (UCP1), peroxisome-proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α) and beta (PGC1β) in the BAT ([Figures 2](#fig2){ref-type="fig"}C and 2D), while no changes in browning markers ([@bib49; @bib35; @bib9]) were detected in white adipose tissue (WAT) ([Figure S2](#app2){ref-type="sec"}A). Peripheral administration of E2 induced a slight upregulation of the thermogenic program in liver but not in skeletal muscle ([Figures S2](#app2){ref-type="sec"}B and S2C). No changes in inflammatory markers were detected in muscle either ([Figure S2](#app2){ref-type="sec"}C).

Next, we examined the possibility that these effects of E2 are centrally mediated. We found that ICV administration of E2 induced weight loss that was significantly larger than that observed in OVX pair-fed animals ([Figures 2](#fig2){ref-type="fig"}E and 2F). Consistently, the mRNA expression or protein content of UCP1, PGC1α, and PGC1β was markedly increased in BAT of ICV E2-treated rats when compared to both vehicle-treated and pair-fed animals ([Figures 2](#fig2){ref-type="fig"}G and 2H), whereas no changes in browning markers were found in WAT ([Figure S2](#app2){ref-type="sec"}D). No increase in the expression of thermogenic or inflammatory markers was detected in the liver or muscle after ICV E2 administration ([Figures S2](#app2){ref-type="sec"}E and S2F).

Central E2 Increases Energy Expenditure and SNS Activity and Inhibits Hypothalamic AMPK {#sec2.3}
---------------------------------------------------------------------------------------

ICV E2-treated (5 nmol) rats showed decreased weight ([Figure 3](#fig3){ref-type="fig"}A), anorexia ([Figure 3](#fig3){ref-type="fig"}B), as well as a significantly higher body temperature ([Figure 3](#fig3){ref-type="fig"}C) and energy expenditure (EE) ([Figure 3](#fig3){ref-type="fig"}D) associated with reduced respiratory quotient (RQ) (which indicates increased lipid mobilization; [Figure 3](#fig3){ref-type="fig"}E) and locomotor activity (LA) ([Figure 3](#fig3){ref-type="fig"}F), which overall promote a negative energy balance ([Figure S3](#app2){ref-type="sec"}A). Notably, a single ICV administration of E2 caused a marked increase in BAT sympathetic nerve traffic recorded directly by microneurography ([Figure 3](#fig3){ref-type="fig"}G). ICV E2 also decreased AMPK activation in the mediobasal hypothalamus (MBH) ([Figure 3](#fig3){ref-type="fig"}H).

Central E2 Induces BAT Thermogenesis through the SNS {#sec2.4}
----------------------------------------------------

In order to further investigate whether ICV E2-induced increase in thermogenic markers correlated with changes in BAT thermogenesis, we used thermographic imaging analysis ([@bib24; @bib51]). Of note, a lower ICV E2 dosage was used in these experiments. A total of 1 nmol of ICV E2 induced a marked weight loss, anorexia, and an increase in core temperature ([Figure 4](#fig4){ref-type="fig"}A). The increase in body temperature was associated with elevated UCP1 protein levels in BAT ([Figure 4](#fig4){ref-type="fig"}B) and a significant rise in the temperature of the skin surrounding interscapular BAT ([Figure 4](#fig4){ref-type="fig"}C), indicating elevated thermogenesis. No changes were detected in WAT browning program after ICV treatment with E2 ([Figure S4](#app2){ref-type="sec"}A). The effects evoked by ICV E2 are not related to leakage of E2 from the cerebrospinal fluid, because circulating levels of E2 remain unchanged after ICV treatment ([Figure S4](#app2){ref-type="sec"}B).

AMPK in VMH plays a major role in the modulation of BAT thermogenesis ([@bib23; @bib24; @bib51]). Thus, we aimed to investigate whether ICV E2 elicits changes in VMH AMPK signaling with ARC samples used as control. The specificity of the VMH and ARC dissections was confirmed by analyzing the mRNA of specific markers, namely SF1 and POMC, respectively ([Figure S4](#app2){ref-type="sec"}C). We found that ICV administration of 1 nmol of E2 elicited similar changes to those observed in the MBH after 5 nmol of the hormone, namely decreased VMH AMPK activity ([Figure 4](#fig4){ref-type="fig"}D). ICV administration of 0.5 nmol of E2 also induced weight loss, anorexia, increased UCP1 in BAT, and decreased hypothalamic AMPK signaling (data not shown). No changes were found in the ARC AMPK pathway after ICV E2 injections ([Figure S4](#app2){ref-type="sec"}D). Of note, the effect of ICV E2 administration was not related to increased inflammatory responses in the VMH (where, in fact, inflammatory markers showed reduced expression) ([Figure S4](#app2){ref-type="sec"}E) or muscle ([Figure S4](#app2){ref-type="sec"}F).

Given that ICV E2 induced a marked increase in the activity of the SNS subserving BAT, we aimed to investigate whether adrenergic receptors blockade impact the central effect of ICV E2 on BAT thermogenic program. Central administration of 1 nmol of E2 was reversed (in a feeding-independent manner) by pharmacological blockade of beta 3 adrenergic receptor (β3-AR) with the specific antagonist SR59230A ([@bib23]) ([Figures 4](#fig4){ref-type="fig"}E and 4F). The increase in body weight induced by SR59230A was associated with appropriate reversal of ICV E2-induced activation of temperature ([Figure 4](#fig4){ref-type="fig"}G) and BAT UCP1 expression ([Figure 4](#fig4){ref-type="fig"}H).

E2 within the VMH Regulates Hypothalamic AMPK and BAT Thermogenic Program {#sec2.5}
-------------------------------------------------------------------------

We performed stereotaxic administration of E2 into the VMH or the ARC. To assess the effects of E2 in both hypothalamic nuclei, we performed anatomical analysis of the injection routes, as well as a combined injection of vehicle or E2 with fluorescein-isothiocyanate (FITC), which allowed us to control the diffusion of the treatment. Both VMH and ARC injections were specific, and the treatment did not spread to other hypothalamic areas ([Figure 5](#fig5){ref-type="fig"}A); moreover, no damage in VMH or ARC structures was found when the sections were stained with toluidine blue ([Figure S5](#app2){ref-type="sec"}A). We found that administration of E2 in the VMH, but not in the ARC, induced a significant rise in temperature ([Figure 5](#fig5){ref-type="fig"}B) associated with an upregulation of BAT UCP1 at both mRNA and protein levels ([Figure 5](#fig5){ref-type="fig"}C). In order to confirm these data using an alternative approach, we used microdialysis, which recapitulated the E2-induced increase in BAT UCP1 ([Figure S5](#app2){ref-type="sec"}C). To better control for the specificity of VMH administration, we performed "missed" E2 injections, in "VMH-neighboring" areas without affecting the VMH ([Figure S5](#app2){ref-type="sec"}D). Our anatomical data showed that when VMH was not "hit" (as indicated by the absence of FITC in this nucleus), no changes in UCP1 expression in the BAT were detected ([Figure S5](#app2){ref-type="sec"}E). This evidence indicates that the effect of E2 on BAT thermogenic program is specific of the VMH and it is not related to E2 spreading to adjacent areas. In line with the temperature and anatomical data, administration of E2 into the ARC did not affect the expression of thermogenic markers in the BAT ([Figure 5](#fig5){ref-type="fig"}D). In addition, these effects are not related to leakage or diffusion of central E2 from the brain, because circulating levels of E2 remained unchanged after VMH and ARC injections ([Figure S5](#app2){ref-type="sec"}F).

We then assessed the effect of VMH and ARC E2 injection on the central mechanism modulating BAT thermogenic program. Rats receiving E2 in the VMH (but not ARC) displayed a significant increase in neuronal activation in the inferior olive (IO) and the raphe pallidus (RPa), as defined by c-FOS staining ([Figure 5](#fig5){ref-type="fig"}E). The RPa and IO have been involved in the sympathetic activation of BAT in response to cold ([@bib43; @bib47; @bib4; @bib3]). We also analyzed the effect of specific stereotaxic injection of E2 on the AMPK pathway in the VMH versus ARC. The administration of E2 into the VMH decreased the protein levels of pAMPK and pACC in this nucleus ([Figure 5](#fig5){ref-type="fig"}F; left images and graph). In contrast, no effect was detected on AMPK pathway when E2 was microinjected into the ARC ([Figure 5](#fig5){ref-type="fig"}F; right images and graph). AMPK is activated by phosphorylation of upstream kinases. The main upstream AMPK kinases are the tumor suppressor LKB1 and Ca^2+^/calmodulin-dependent protein kinase kinase alpha and beta (CaMKKα and CaMKKβ), which phosphorylate AMPK at Thr172; AMPK phosphorylation levels are also regulated by protein phosphatase-2Cα (PP2Cα) ([@bib5; @bib15]). We found that 2 hr after specific VMH E2 injection, the protein levels of CaMKKα and pLKB1 were decreased, whereas the levels of PP2Cα were increased in the VMH ([Figure 5](#fig5){ref-type="fig"}G). Consistent with these data, AMPK phosphorylation status was also reduced 2 hr after E2 treatment in the VMH ([Figure S5](#app2){ref-type="sec"}G). Finally, E2 caused no changes in the activity of PI3K and AKT signaling in the VMH (just an increase in total AKT levels; [Figure 5](#fig5){ref-type="fig"}H), and as previously described ([@bib11]), E2 induced a marked increase in the pSTAT3 levels in the VMH ([Figure 5](#fig5){ref-type="fig"}H).

Activation of AMPK in the VMH Reverses the Central Action of E2 {#sec2.6}
---------------------------------------------------------------

To elucidate the contribution of AMPK activity in the VMH to the thermogenic program in the BAT after E2 central treatment, adenoviruses encoding constitutively active AMPKα-CA, together with GFP or control adenovirus expressing GFP alone ([@bib27; @bib22; @bib23; @bib24; @bib51]), were injected stereotaxically into the VMH or the ARC of OVX rats treated with vehicle or E2. Infection efficiency was assessed by (a) expression of GFP in the VMH ([Figure 6](#fig6){ref-type="fig"}A) or in the ARC ([Figure 6](#fig6){ref-type="fig"}E) and (b) increased phosphorylation of ACCα ([Figure S6](#app2){ref-type="sec"}A). Quantification analyses showed that when the injections were directed to the VMH, the vast majority of GFP-positive cells (98.4%) reside in the VMH ([Figure S6](#app2){ref-type="sec"}B). On the other hand, when the ARC was targeted, we achieved a similar level of specificity with 95% of GFP-positive cells in this nucleus ([Figure S6](#app2){ref-type="sec"}C). Administration of AMPKα-CA adenoviruses into the VMH reversed the weight loss in OVX rats treated with E2 ([Figure 6](#fig6){ref-type="fig"}B) with no alteration in food intake ([Figure 6](#fig6){ref-type="fig"}C). Overexpression of AMPKα-CA in the VMH was also associated with a reduction in expression of UCP1, PGC1α, and PGC1β in the BAT, as well as reduced core temperature, of OVX rats treated with E2 ([Figure 6](#fig6){ref-type="fig"}D). This effect was VMH specific, since AMPKα-CA adenoviruses injected into the ARC of OVX rats treated with E2 caused a slight increase in body weight in comparison to E2 GFP-treated rats ([Figure 6](#fig6){ref-type="fig"}F), which was associated with increased feeding ([Figure 6](#fig6){ref-type="fig"}G) but unaltered expression of thermogenic markers in the BAT ([Figure 6](#fig6){ref-type="fig"}H).

A particular feature of adenoviral experiments is that administration of AMPKα-CA had no effect on body weight per se in OVX animals treated with vehicle. A possible explanation for this is that AMPK was already maximally activated in the OVX state (data not shown). Thus, we determined whether chronic inactivation of AMPK in the VMH or the ARC can alter markers of BAT activation of OVX rats. Stereotaxic delivery of a dominant-negative isoform of AMPKα (AMPKα-DN) ([Figure S6](#app2){ref-type="sec"}A) into the VMH, but not into the ARC, caused feeding-independent weight loss that began on the day following the injection ([Figures S6](#app2){ref-type="sec"}D, S6E, S6G and S6H). Administration of AMPKα-DN into the VMH, but not into the ARC, of OVX rats increased the expression of UCP-1, PGC1α, and PGC1β in the BAT ([Figures S6](#app2){ref-type="sec"}F and S6I).

The Physiological Actions of VMH E2 Are Mediated through ERα {#sec2.7}
------------------------------------------------------------

To gain further insight into the physiological effects of endogenous E2 on the aforementioned VMH AMPK-SNS-BAT axis, we studied female rats at diestrus that display low-to-mid circulating levels of E2, in contrast to preovulatory animals with peak E2 concentrations ([Figures S1](#app2){ref-type="sec"}B and [7](#fig7){ref-type="fig"}A). Diestrus rats had higher core temperature ([Figure 7](#fig7){ref-type="fig"}A) and BAT UCP1 protein levels ([Figure 7](#fig7){ref-type="fig"}B) than OVX rats, as well as decreased AMPK signaling in the VMH ([Figure 7](#fig7){ref-type="fig"}C). Consistent with these data, ICV administration of the combined ERα-β antagonist ICI 182.780 ([@bib31]) to intact female rats induced feeding-independent weight gain ([Figure S7](#app2){ref-type="sec"}A) in association with decreased UCP1 expression in the BAT ([Figure S7](#app2){ref-type="sec"}B) and increased AMPK signaling in the VMH ([Figure S7](#app2){ref-type="sec"}C).

ICV injections of the specific ERα antagonist MPP ([@bib45]) to intact female rats induced weight gain and a tendency for food intake to increase ([Figure 7](#fig7){ref-type="fig"}D) in association with decreased BAT UCP1 expression ([Figure 7](#fig7){ref-type="fig"}E) and increased AMPK signaling in the VMH ([Figure 7](#fig7){ref-type="fig"}F). In keeping with this, ICV administration of the specific ERα agonist PPT ([@bib40; @bib41; @bib37]) to OVX rats recapitulated the effects of E2 by eliciting weight loss and anorexia ([Figure S7](#app2){ref-type="sec"}D), associated with increased UCP1 expression in BAT ([Figure S7](#app2){ref-type="sec"}E) and reduced AMPK signaling in the VMH ([Figure 7](#fig7){ref-type="fig"}F). VMH administration of a lentivirus encoding an shRNA that silence ERα to intact female rats induced weight gain without changes in feeding behavior ([Figure 7](#fig7){ref-type="fig"}G) and simultaneous decrease in UCP1 expression in BAT ([Figure 7](#fig7){ref-type="fig"}H) and an increase in AMPK signaling in the VMH ([Figure 7](#fig7){ref-type="fig"}I). Conversely, overexpression of a wild-type isoform of ERα in the VMH of OVX rats, using adenoviral vector, induced feeding-independent weight loss ([Figure S7](#app2){ref-type="sec"}G) in association with increased BAT UCP1 expression ([Figure S7](#app2){ref-type="sec"}H) and decreased AMPK signaling in the VMH ([Figure S7](#app2){ref-type="sec"}I).

Discussion {#sec3}
==========

This study identifies a link between the effects of E2 on hypothalamic AMPK and BAT thermogenesis. Specifically, we show that activation of BAT thermogenic program and subsequent energy expenditure depends on ERα-mediated inactivation of VMH AMPK. Overall, these results offer a physiological mechanism, via the energy sensor AMPK, for the central actions of E2 on ERα that is of relevance in linking the changes in energy balance and obesity-associated alterations in the gonadal axis.

Conditions in which ovarian estrogens are lacking, such as OVX or menopause, are associated with hyperphagia and decreased caloric expenditure that results in a positive energy balance leading to obesity. Estrogen replacement reverts this phenotype both in women and female rodents ([@bib6; @bib10; @bib39; @bib53; @bib8; @bib25]). Recent evidence indicates that hypothalamic kisspeptin/neurokinin B/dynorphin neurons promote cutaneous vasodilatation and participate in the E2 modulation of body temperature ([@bib28; @bib36]). Also, genetic models have shown that some of the actions of estrogens on energy homeostasis are centrally mediated through activation of ERα in key hypothalamic nuclei, such as the ARC and the VMH ([@bib32; @bib54]). In this regard, compelling data have demonstrated that E2, the most important ovarian estrogen, inhibits feeding in a leptin-independent (but STAT3-dependent) manner, acting on POMC, NPY, and melanin-concentrating hormone (MCH) neurons in the hypothalamus ([@bib33; @bib11]). Furthermore, it has been proposed that E2 modulates ghrelin signaling and that this endocrine interaction may account for important sex differences in the regulation of food intake ([@bib7]). However, E2 action on feeding does not explain the entire change in body weight, as shown here in experiments assessing the effect of estrogens in pair-fed animals.

Recent literature indicates that hypothalamic AMPK pathway is a central regulator of energy homeostasis that acts by controlling both feeding and energy dissipation ([@bib27; @bib22; @bib23; @bib1; @bib24; @bib51]). Therefore, we hypothesized that E2-induced actions on energy balance could be mediated by hypothalamic AMPK. Our data showed that peripheral administration of E2 induced a negative energy balance in obese and hyperphagic OVX rats, associated with inactivation of AMPK signaling and increased malonyl-CoA levels in the hypothalamus. Notably, central pharmacological activation of AMPK, using AICAR, was able to restore hypothalamic malonyl-CoA concentration and reversed the anorectic effect evoked by E2 administration. Overall, these data indicate that hypothalamic AMPK mediated the actions of E2 on energy balance. These results are in line with previous evidence suggesting an anabolic role for AMPK in the hypothalamus, which is in contrast with its peripheral catabolic function ([@bib26; @bib27; @bib34]). Of note, the effects of peripherally administered E2 were recapitulated by its central injection. ICV administration of E2 promoted a state of negative energy balance, characterized by hypophagia, increased energy expenditure, and BAT thermogenesis, leading to marked weight loss. This effect was associated with a robust decrease in hypothalamic AMPK signaling, neuronal activation in RPa and IO (two nuclei which have been functionally linked to the regulation of BAT thermogenesis) ([@bib29; @bib43; @bib47; @bib4; @bib30]), and increased SNS tone to BAT. While based on the literature we do believe that our activation (c-FOS) data in IO and caudal RPa are related to BAT activity, we cannot rule out the possibility that at least part of the responses observed might be related to other functions, such as motor control, as previously described ([@bib50; @bib2]). Importantly, the above effects are reversed by pharmacological blockage of β3-AR and appear to derive from VMH-specific actions of E2, so that the impact of E2 on BAT thermogenesis derives from its ability to modulate AMPK activity in the VMH. Interestingly, when E2 was given in the neighboring ARC, which has been primarily involved in the regulation of feeding rather than energy expenditure ([@bib52; @bib55]), no effect was detected on BAT thermogenic program. Likewise, genetic activation of AMPK within the VMH, but not in the ARC, abolished the effect of central E2 on BAT program markers. In contrast, genetic activation of AMPK in the ARC reversed E2 anorectic action but had no effects on BAT function.

Overall, these data confirm that E2 modulates energy homeostasis in a brain site-specific fashion ([@bib54]) and uncover a molecular mechanism (i.e. modulation of AMPK, by which E2 specifically modulates BAT metabolism). Also, in agreement with elegant studies from Clegg and colleagues ([@bib17; @bib32; @bib54]), our data using pharmacological and viral approaches also suggest that the effect of E2 on the VMH AMPK-SNS-BAT axis is mediated by ERα. Remarkably, physiological fluctuations in E2 levels during estrous cycle and blockade of E2 actions also modulate the aforementioned axis, indicating that this integrative response is not a particular phenomenon restricted to conditions of estrogen deficiency, such as OVX, but also a mechanism of relevance in the physiological regulation of energy homeostasis by ovarian estrogens.

In recent years, hypothalamic metabolic energy sensors, such as AMPK, have been suggested to play a major role in the regulation of energy homeostasis. Several metabolic hormones, such as leptin, ghrelin, insulin, and thyroid hormones ([@bib27; @bib1; @bib22; @bib23]), and more recently bone morphogenetic protein 8b (BMP8b) ([@bib51]), have been shown to regulate energy balance acting through those energy sensors. Here, we provide evidence that E2, a hormone that markedly influences energy and metabolic homeostasis, acts on the same sensors to control both feeding and energy expenditure. Notably, the mechanisms described here for the thermogenic actions of E2 display considerable commonalities with those previously unveiled by our group for thyroid hormone and BMP8b ([@bib23; @bib51]). Thus, the VMH AMPK-SNS-BAT axis appears to act as a canonical central mechanism integrating central and peripheral regulation of energy stores. In this regard, our data points to AMPK in the VMH as a potential target for the treatment of obesity and other metabolic disorders associated to conditions of endocrine deregulation. The relevance of such a pharmacological target is emphasized by recent reports showing that nicotine-induced anorexia and weight loss is in part mediated by actions on AMPK-expressing neurons in the VMH to increase energy expenditure ([@bib24]), which could be exploited as a potential therapeutic strategy. In addition, DiMarchi, Tschop, and colleagues have recently reported an elegant approach based on the development of a combinatorial peptide of a glucagon-like peptide-1 (GLP-1)-estrogen conjugate for the treatment of obesity and metabolic syndrome ([@bib8]). They demonstrated that selective activation of ERs in GLP-1-targeted tissues enhances the benefits of both E2 and GLP-1 agonism on body weight, glucose homeostasis, and lipid metabolism. Considering that both GLP-1 receptor and ERα are highly expressed in the VMH ([@bib44; @bib14]) raises the possibility that the metabolic benefits of E2 and GLP-1 agonism may be mediated by selective modulation of AMPK in the VMH. However, further investigations are needed to test such possibility.

In summary, we show that central E2 inactivates AMPK in the VMH through ERα, which increases SNS tone, upregulates BAT thermogenesis, and increases energy expenditure, leading to weight loss. Thus, our data add more evidence to the fact that AMPK, specifically in the VMH, is a canonical mechanism modulating energy dissipation via SNS activation of BAT. This observation provides insights into the physiological regulation of energy balance and its perturbation in estrogen-deficient states and suggests that the VMH AMPK-SNS-BAT axis may be a potential therapeutic target for the treatment of obesity.

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

Female Sprague-Dawley and Wistar Unilever (for the microdialysis experiments) rats (250--300 g; Animalario General USC, Santiago de Compostela, Spain; Harlan, Horst, The Netherlands; and Charles River, Wilmington) were used for the experiments. All animals were housed on a 12 hr light (8:00 to 20:00) 12 hr dark cycle, in a temperature- and humidity-controlled room. The animals were allowed free access to standard laboratory pellets of rat chow and tap water. The experiments were performed in agreement with the International Law on Animal Experimentation and were approved by the USC Local Ethical Committee and the Ministry of Science and Innovation of Spain (Project ID PI12/01814), Animal Experimental Committee of the AMC, and the University of Iowa Institutional Animal Care and Use Committee.

OVX {#sec4.2}
---

Sprague-Dawley rats were bilaterally ovariectomized (OVX) or sham operated, as described previously, under ketamine/xylacine anesthesia (50 mg/kg, intraperitoneally) ([@bib48; @bib38; @bib21]). All treatments (central or peripheral) on OVX rats were carried out 2 weeks after surgery to ensure a total washout of endogenous ovarian hormones. For the experiments of E2 replacement, OVX rats received a daily SC injection of E2 (estradiol benzoate; EB, 2 μg dissolved in 100 μL of sesame oil; both from Sigma; Saint Louis) or vehicle (100 μL of sesame oil; control rats) during 7 days. EB was chosen for SC administration, as this synthetic estrogen is endowed with higher bio-potency and stability and it has been often used in various protocols of peripheral estrogenization ([@bib7; @bib37]).

Central and Peripheral Treatments {#sec4.3}
---------------------------------

Chronic ICV cannulae were implanted as described previously (see [Supplemental Experimental Procedures](#app2){ref-type="sec"}). We used 17β-estradiol (17β-E2, as the major endogenous estrogen) in our central (ICV, VMH, or ARC) experiments in a mix DMSO:saline (1:10). Intact female (see below) or OVX rats were subjected to a protocol of daily ICV injections of *17β-E2* (0.5 nmol, 1 nmol, or 5 nmol dissolved in 5 μl of saline containing 10% of DMSO; Sigma; Saint Louis) or vehicle (5 μl of saline containing 10% of DMSO; control rats) for 3--7 days. For the experiments of pharmacological AMPK activation, rats were ICV treated with AICAR (5 μg dissolved in 5 μl of DMSO; Sigma, Saint Louis) or vehicle (5 μl of DMSO), for 2 and 4 hr. For the experiments of ER stimulation of blockage, we used ICV administration of the following: (a) the selective estrogen receptor alpha (ERα) agonist PPT (1 nmol dissolved in 5 μL of saline containing 10% of DMSO; TOCRIS Bioscience, Bristol) ([@bib37]), (b) the combined ERα-β antagonist named ICI 182.780 (2.5 nmol dissolved in 5 μl of saline containing 10% of DMSO; TOCRIS Bioscience, Bristol) ([@bib31]), (c) and the specific ERα antagonist MPP (2.5 nmol dissolved in 5 μl of saline containing 10% of DMSO; TOCRIS Bioscience, Bristol) ([@bib16]). Both ICI 182.780 and MPP were administrated to intact female rats. The β3-AR specific antagonist SR59230A (3 mg/kg/day; Tocris Bioscience, Bristol) ([@bib23]) was administrated subcutaneously, starting during 2 days before the ICV E2 injections. For more details of implantation of microdialysis probes and central treatments, see [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Stereotaxic Treatments of E2 and Viral Vectors {#sec4.4}
----------------------------------------------

Freely moving rats were treated within the VMH or ARC with 17β-E2 (Sigma, Saint Louis; 0.1 nmol in 1 μl of saline containing 10% of DMSO) or vehicle (1 μl of saline containing 10% of DMSO) during 2 or 12 hr. FITC (Sigma, Saint Louis) was used to control the diffusion of the treatment. Adenoviral (GFP, AMPKα-CA, or AMPKα-DN: Viraquest, North Liberty; ERα wildtype: Signagen; Rockville) or lentiviral (GFP, ERα shRNA; Santa Cruz Biotechnology; Santa Cruz) were stereotaxically delivered as previously reported ([@bib22; @bib23; @bib24; @bib51; @bib42]). Animals were treated for 5--7 days in the case of adenoviruses and 16 days in the case of lentiviruses, due to the longer infective period needed.

Sample Processing and Analytical Methods {#sec4.5}
----------------------------------------

Sample processing, analysis of EE, LA, and RQ; nuclear magnetic resonance analysis; sympathetic nerve activity (SNA) recording; temperature measurements; E2, LH, and malonyl-CoA assays; and real-time quantitative PCR, in situ hybridization, western blotting, and immunohistochemistry were performed as previously shown ([@bib22; @bib23; @bib24; @bib51; @bib42]) (see [Supplemental Experimental Procedures](#app2){ref-type="sec"} for detailed protocols).

Statistical Analysis {#sec4.6}
--------------------

Data are expressed as mean ±SEM. mRNA and protein data were expressed in relation (%) to control (vehicle-treated) rats. Error bars represent SEM. Statistical significance was determined by Student's t test when two groups were compared or ANOVA and post hoc two-tailed Bonferroni test when more than two groups were compared. p \< 0.05 was considered significant.
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![Effect of SC E2 on Energy Balance\
(A--F) (A) Body weight change, (B) daily food intake, (C) in situ hybridization autoradiographic images, (D) *Npy* and *Pomc* mRNA levels in the ARC, (E) western blot autoradiographic images (left panel) and hypothalamic levels of proteins of AMPK pathway (right panel), and (F) hypothalamic malonyl-CoA levels of OVX rats and OVX rats SC treated with vehicle or E2.\
(G and H) (G) Hypothalamic malonyl-CoA levels and (H) food intake of OVX rats SC treated with vehicle or E2 and ICV treated with vehicle or AICAR. Error bars represent SEM; n = 8--16 animals per experimental group. 3V: third ventricle; ^∗^, ^∗∗^ and ^∗∗∗^p \< 0.05, 0.01, and 0.001 *vs*. OVX E2 SC or vehicle SC vehicle ICV; \#p \< 0.05 E2 SC vehicle *ICV* versus E2 SC AICAR ICV; \#\#\#p \< 0.001 versus sham or E2 SC vehicle ICV versus E2 SC AICAR ICV.](gr1){#fig1}

![Effect of SC and ICV E2 on BAT Thermogenic Markers\
(A--D) (A) Body weight change, (B) daily food intake, (C) mRNA expression profile in the BAT, and (D) protein levels (upper panel) and western blot autoradiographic images of BAT UCP1 protein (lower panel) of OVX rats treated with vehicle or E2 SC and pair-fed (PF) rats.\
(E--H) (E) Body weight change, (F) daily food intake, (G) mRNA expression profile in the BAT, and (H) protein levels (upper panel) and western blot autoradiographic images of BAT UCP1 protein (lower panel) of OVX rats treated with vehicle or E2 ICV (5 nmol) and pair-fed rats. Error bars represent SEM; n = 8--20 animals per experimental group. ^∗^, ^∗∗^, and ^∗∗∗^p \< 0.05, 0.01, and 0.001 versus *v*ehicle (SC or ICV); \#, \#\#, and \#\#\#p \< 0.05, 0.01, and 0.001 versus E2 (SC or ICV).](gr2){#fig2}

![Effect of ICV E2 on Energy Balance, BAT Activation, and Hypothalamic AMPK Pathway\
(A--H) (A) Body weight change, (B) daily food intake, (C) core temperature, (D) energy expenditure (EE) (cumulative in left panel and total in right panel), (E) respiratory quotient (RQ) (cumulative in left panel and total in right panel), (F) locomotor activity (LA) (cumulative in left panel and total in right panel), (G) BAT sympathetic nervous activity (SNA) tracings (upper panel) and time-course of BAT SNA response (lower panel), and (H) western blot autoradiographic images (left panel) and hypothalamic protein levels of proteins of the AMPK pathway (right panel) of OVX rats ICV treated with vehicle or E2 (5 nmol). Error bars represent SEM; n = 6 (SNA recordings) or 8--12 animals per experimental group. ^∗^, ^∗∗^, and ^∗∗∗^p \< 0.05, 0.01, and 0.001 *vs. v*ehicle ICV.](gr3){#fig3}

![Effect of ICV E2 on Energy Balance and the VMH AMPK-SNS-BAT Axis\
(A--D) (A) Body weight change (left panel), daily food intake (middle panel), and core temperature (right panel); (B) protein levels (upper panel) and western blot autoradiographic images of BAT UCP1 protein (lower panel); (C) infrared thermal images (left panel) and quantification of temperature of the skin surrounding interscapular BAT (right panel); and (D) western blot autoradiographic images (left panel) and VMH protein levels of proteins of the AMPK pathway (right panel) of OVX rats ICV treated with vehicle or E2 (1 nmol).\
(E--H) (E) Body weight change, (F) daily food intake, (G) core temperature, and (H) western blot autoradiographic images of BAT UCP1 protein (left panel) and UCP1 protein levels (right panel) of OVX rats ICV treated with vehicle or E2 (1 nmol), previously SC treated with the β3-AR-antagonist SR59230A for 2 days. Error bars represent SEM; n = 7--12 animals per experimental group. ^∗^ and ^∗∗∗^p \< 0.05 and 0.001 versus vehicle ICV or vehicle ICV vehicle SC; \# and \#\#p \< 0.05 and 0.01 versus E2 ICV vehicle SC.](gr4){#fig4}

![Effect of E2 within the VMH or ARC on BAT Thermogenic Markers, Central SNS Outflow, and Hypothalamic AMPK Pathway\
(A) Representative photomicrographs of brain sections showing the injection route enclosed in a red rectangle, precisely placed in the VMH or ARC (10×, left panel), and immunofluorescence of brain sections (20×) showing the presence of the dye (FITC) after comicroinjection with E2 within the VMH or the ARC.\
(B and C) (B) Core temperature and (C) mRNA expression profile in the BAT (left panel), protein levels (right-upper panel), and western blot autoradiographic images of BAT UCP1 (right-lower panel) of OVX rats stereotaxically treated with vehicle or E2 within the VMH.\
(D) mRNA expression profile in the BAT (left panel), protein levels (right-upper panel), and western blot autoradiographic images of BAT UCP1 (right-lower panel) of rats stereotaxically treated with vehicle or E2 within the ARC.\
(E) Representative photomicrographs (upper: 1.25×, lower 10×) showing immunohistochemistry of c-FOS (left panel) and c-FOS immunoreactive (IR) (right panel) cells in the inferior olive (IO) and the raphe pallidus (RPa) nuclei of OVX rats stereotaxically treated with vehicle or E2 within the VMH or ARC.\
(F) Western blot autoradiographic images (left panels) and levels of proteins of the AMPK pathway (right panels) in the VMH or ARC of OVX rats stereotaxically treated with vehicle or E2 within the VMH (left images and graph) and the ARC (right images and graph); thus, when injection of E2 was performed in the VMH, the AMPK pathway was analyzed in the VMH, and when injection of E2 was performed in the ARC, the AMPK pathway was analyzed in the ARC.\
(G and H) Western blot autoradiographic images (left panels) and protein levels (right panels) of (G) upstream kinases of AMPK and (H) PI3K/AKT pathway (left images and graph) and pSTAT3/STAT (right images and graph) in the VMH of OVX rats stereotaxically treated with vehicle or E2 within the VMH. Error bars represent SEM; n = 5 (c-FOS analysis) or 7--8 animals per experimental group. Gi: gigantocellular reticular nucleus; IO: inferior olive; ME: median eminence; py: pyramidal tract; RPa: raphe pallidus nucleus. ^∗^, ^∗∗^ and ^∗∗∗^p \< 0.05, 0.01, and 0.001 *vs. v*ehicle VMH. In (A), it is important to note that the figure oversimplifies the protocol, since injections were given bilaterally.](gr5){#fig5}

![Effect of Activation of Hypothalamic AMPK on the Central Actions of E2 on Energy Balance\
(A) Representative immunofluorescence (20×) with anti-GFP antibody showing GFP expression in the VMH of OVX rats treated with adenoviruses encoding AMPKα-CA within the VMH.\
(B--D) (B) Body weight change, (C) daily food intake, and (D) mRNA expression profile in the BAT (left panel) and core temperature (at 24 hr, right panel) of OVX rats SC treated with vehicle or E2 (VMH in \[D\], right) and stereotaxically treated with GFP or AMPKα-CA adenoviruses within the VMH.\
(E) Representative immunofluorescence (20×, left panel, and 40×, right panel) with anti-GFP antibody showing GFP expression in the ARC of rats treated with adenoviruses encoding AMPKα-CA within the ARC.\
(F--H) (F) Body weight change, (G) daily food intake, and (H) mRNA expression profile in the BAT of OVX rats SC treated with vehicle or E2 and stereotaxically treated with GFP or AMPKα-CA adenoviruses within the ARC. Error bars represent SEM; n = 8--17 animals per experimental group. 3V: third ventricle; ^∗^, ^∗∗^, and ^∗∗∗^p \< 0.05 and 0.01 *vs. v*ehicle GFP VMH or ARC; \#, \#\# and \#\#\# p \< 0.05 and 0.01versus E2 GFP VMH or ARC.](gr6){#fig6}

![Effect of Physiological Levels of E2 and Pharmacological and Genetic Manipulation of ERα on the VMH AMPK-SNS-BAT Axis\
(A--C) (A) Serum E2 levels (left panel) and core temperature (right panel), (B) protein levels (upper panel) and western blot autoradiographic images of BAT UCP1 protein (lower panel), and (C) western blot autoradiographic images (left panel) and levels of proteins of AMPK pathway in the VMH (right panel) of diestrus cycled rats.\
(D--F) (D) Body weight change (left panel) and daily food intake (right panel), (E) protein levels (upper panel) and western blot autoradiographic images of BAT UCP1 protein (lower panel), and (F) western blot autoradiographic images (left panel) and levels of proteins of AMPK pathway in the VMH (right panel) of intact rats ICV treated with the specific ERα antagonist MPP.\
(G--I) (G) Body weight change (left panel) and daily food intake (right panel), (H) protein levels (upper panel) and western blot autoradiographic images of BAT UCP1 protein (lower panel), and (I) western blot autoradiographic images (left panel) and levels of proteins of AMPK pathway in the VMH (right panel) of intact rats stereotaxically treated within the VMH with lentivirus encoding short hairpin RNA of the ERα. Error bars represent SEM; n = 7--8 animals per experimental group. ^∗^, ^∗∗^, and ^∗∗∗^p \< 0.05, 0.01, and 0.001 versus OVX, vehicle ICV, or GFP VMH.](gr7){#fig7}
